NCT00249834View on ClinicalTrials.gov

Safety and Efficacy of Pre-defined, Fixed Dose of Gonal-f Pen Based on Subject Baseline Characteristics in Subjects Undergoing in Vitro Fertilization (IVF)

PHASE4CompletedINTERVENTIONAL
Enrollment

166

Participants

Timeline

Start Date

September 22, 2004

Primary Completion Date

January 16, 2006

Study Completion Date

January 16, 2006

Conditions
Infertility
Interventions
DRUG

Gonal-f

GONAL-f (follitropin alfa) will be administered subcutaneously based on ART treatment guidelines, which determined the optimal dose of r-hFSH based on subject baseline characteristics/predictors of ovarian response throughout stimulation cycle.

DRUG

Recombinant human chorionic gonadotrophin (r-hCG)

When at least 1 follicle greater than or equal to (\>=) 18 millimeter (mm) and 2 follicles \>=16 mm in diameter develop, 250 microgram (mcg) of recombinant human chorionic gonadotrophin (r-hCG) will be administered.

Trial Locations (1)

Unknown

Medical Information, Paris

All Listed Sponsors
lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT00249834 - Safety and Efficacy of Pre-defined, Fixed Dose of Gonal-f Pen Based on Subject Baseline Characteristics in Subjects Undergoing in Vitro Fertilization (IVF) | Biotech Hunter | Biotech Hunter